Industry News Archives | International Rett Syndrome Foundation

June 30, 2025

Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome (Community Letter)

Filter

Neurogene

Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome (Community Letter)

Neurogene

Neurogene Announces Registrational Trial Design for Embolden™ Study of NGN-401 Gene Therapy for Rett Syndrome

Taysha

Taysha Gene Therapies Updates on Part A Data, Plans for the Part B Pivotal Study, and FAQs (Community Letter)

Neurogene

Neurogene Updates on Program & Risk Mitigation Strategies (Community Letter)

Taysha

Taysha Gene Therapies Announces Pivotal Part B Trial Design Details for TSHA-102 in Rett Syndrome Enabled by IRSF Natural History Data and Positive Clinical Data from Part A of the REVEAL Adult/Adolescent and Pediatric Trials Evaluating TSHA-102

Acadia

Acadia Pharmaceuticals Announces Recipients of Second Annual Rett Sibling Scholarship

Taysha

Taysha Gene Therapies Reports First Quarter 2025 Financial Results and Provides Corporate Update

Neurotech

European Commission grants NTI64 Orphan Drug Designation for Rett Syndrome

Neurogene

Neurogene Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Updates